Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 428

1.

Integrated multidisciplinary care in Parkinson's disease: a non-randomised, controlled trial (IMPACT).

van der Marck MA, Munneke M, Mulleners W, Hoogerwaard EM, Borm GF, Overeem S, Bloem BR; IMPACT study group.

Lancet Neurol. 2013 Oct;12(10):947-56. doi: 10.1016/S1474-4422(13)70196-0. Epub 2013 Aug 27.

PMID:
23988337
2.

Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): a randomised controlled trial.

Odekerken VJ, van Laar T, Staal MJ, Mosch A, Hoffmann CF, Nijssen PC, Beute GN, van Vugt JP, Lenders MW, Contarino MF, Mink MS, Bour LJ, van den Munckhof P, Schmand BA, de Haan RJ, Schuurman PR, de Bie RM.

Lancet Neurol. 2013 Jan;12(1):37-44. doi: 10.1016/S1474-4422(12)70264-8. Epub 2012 Nov 16.

PMID:
23168021
3.

Effectiveness of multidisciplinary care for Parkinson's disease: a randomized, controlled trial.

van der Marck MA, Bloem BR, Borm GF, Overeem S, Munneke M, Guttman M.

Mov Disord. 2013 May;28(5):605-11. doi: 10.1002/mds.25194. Epub 2012 Nov 19.

PMID:
23165981
4.

Efficacy of community-based physiotherapy networks for patients with Parkinson's disease: a cluster-randomised trial.

Munneke M, Nijkrake MJ, Keus SH, Kwakkel G, Berendse HW, Roos RA, Borm GF, Adang EM, Overeem S, Bloem BR; ParkinsonNet Trial Study Group.

Lancet Neurol. 2010 Jan;9(1):46-54. doi: 10.1016/S1474-4422(09)70327-8. Epub 2009 Dec 1.

PMID:
19959398
5.

Efficacy of occupational therapy for patients with Parkinson's disease: a randomised controlled trial.

Sturkenboom IH, Graff MJ, Hendriks JC, Veenhuizen Y, Munneke M, Bloem BR, Nijhuis-van der Sanden MW; OTiP study group.

Lancet Neurol. 2014 Jun;13(6):557-66. doi: 10.1016/S1474-4422(14)70055-9. Epub 2014 Apr 8. Erratum in: Lancet Neurol. 2016 Apr;15(4):352. Lancet Neurol. 2014 Jun;13(6):536. Lancet Neurol. 2016 Mar;15(3):241.

PMID:
24726066
6.

A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.

Rascol O, Fitzer-Attas CJ, Hauser R, Jankovic J, Lang A, Langston JW, Melamed E, Poewe W, Stocchi F, Tolosa E, Eyal E, Weiss YM, Olanow CW.

Lancet Neurol. 2011 May;10(5):415-23. doi: 10.1016/S1474-4422(11)70073-4. Epub 2011 Apr 7. Erratum in: Lancet Neurol. 2012 Dec;11(12):1021.

PMID:
21482191
7.

Neurostimulation for Parkinson's disease with early motor complications.

Schuepbach WM, Rau J, Knudsen K, Volkmann J, Krack P, Timmermann L, Hälbig TD, Hesekamp H, Navarro SM, Meier N, Falk D, Mehdorn M, Paschen S, Maarouf M, Barbe MT, Fink GR, Kupsch A, Gruber D, Schneider GH, Seigneuret E, Kistner A, Chaynes P, Ory-Magne F, Brefel Courbon C, Vesper J, Schnitzler A, Wojtecki L, Houeto JL, Bataille B, Maltête D, Damier P, Raoul S, Sixel-Doering F, Hellwig D, Gharabaghi A, Krüger R, Pinsker MO, Amtage F, Régis JM, Witjas T, Thobois S, Mertens P, Kloss M, Hartmann A, Oertel WH, Post B, Speelman H, Agid Y, Schade-Brittinger C, Deuschl G; EARLYSTIM Study Group.

N Engl J Med. 2013 Feb 14;368(7):610-22. doi: 10.1056/NEJMoa1205158.

8.

Multidisciplinary rehabilitation for people with Parkinson's disease: a randomised controlled study.

Wade DT, Gage H, Owen C, Trend P, Grossmith C, Kaye J.

J Neurol Neurosurg Psychiatry. 2003 Feb;74(2):158-62.

9.

Treatment effect modifiers for the patient education programme for Parkinson's disease.

A'Campo LE, Wekking EM, Spliethoff-Kamminga NG, Stijnen T, Roos RA.

Int J Clin Pract. 2012 Jan;66(1):77-83. doi: 10.1111/j.1742-1241.2011.02791.x.

PMID:
22171907
10.

Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.

Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, Tolosa E, Weintraub D.

Lancet Neurol. 2010 Jun;9(6):573-80. doi: 10.1016/S1474-4422(10)70106-X. Epub 2010 May 7.

PMID:
20452823
11.

Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.

Parkinson Study Group CALM Cohort Investigators.

Arch Neurol. 2009 May;66(5):563-70. doi: 10.1001/archneur.66.1.nct90001.

PMID:
19433655
12.

Impact of non-motor symptoms on health-related and perceived quality of life in Parkinson's disease.

Santos-García D, de la Fuente-Fernández R.

J Neurol Sci. 2013 Sep 15;332(1-2):136-40. doi: 10.1016/j.jns.2013.07.005. Epub 2013 Jul 25.

PMID:
23890935
13.

Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial.

Marks WJ Jr, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, Vitek J, Stacy M, Turner D, Verhagen L, Bakay R, Watts R, Guthrie B, Jankovic J, Simpson R, Tagliati M, Alterman R, Stern M, Baltuch G, Starr PA, Larson PS, Ostrem JL, Nutt J, Kieburtz K, Kordower JH, Olanow CW.

Lancet Neurol. 2010 Dec;9(12):1164-72. doi: 10.1016/S1474-4422(10)70254-4. Epub 2010 Oct 20.

PMID:
20970382
14.

Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.

Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Musch B, Kamp C, Welsh M, Shinaman A, Pahwa R, Barclay L, Hubble J, LeWitt P, Miyasaki J, Suchowersky O, Stacy M, Russell DS, Ford B, Hammerstad J, Riley D, Standaert D, Wooten F, Factor S, Jankovic J, Atassi F, Kurlan R, Panisset M, Rajput A, Rodnitzky R, Shults C, Petsinger G, Waters C, Pfeiffer R, Biglan K, Borchert L, Montgomery A, Sutherland L, Weeks C, DeAngelis M, Sime E, Wood S, Pantella C, Harrigan M, Fussell B, Dillon S, Alexander-Brown B, Rainey P, Tennis M, Rost-Ruffner E, Brown D, Evans S, Berry D, Hall J, Shirley T, Dobson J, Fontaine D, Pfeiffer B, Brocht A, Bennett S, Daigneault S, Hodgeman K, O'Connell C, Ross T, Richard K, Watts A; Parkinson Study Group.

Arch Neurol. 2004 Jul;61(7):1044-53. Erratum in: Arch Neurol. 2005 Mar;62(3):430.

PMID:
15262734
15.

The clinically important difference on the unified Parkinson's disease rating scale.

Shulman LM, Gruber-Baldini AL, Anderson KE, Fishman PS, Reich SG, Weiner WJ.

Arch Neurol. 2010 Jan;67(1):64-70. doi: 10.1001/archneurol.2009.295.

PMID:
20065131
16.

Longer term clinical and economic benefits of offering acupuncture care to patients with chronic low back pain.

Thomas KJ, MacPherson H, Ratcliffe J, Thorpe L, Brazier J, Campbell M, Fitter M, Roman M, Walters S, Nicholl JP.

Health Technol Assess. 2005 Aug;9(32):iii-iv, ix-x, 1-109.

17.

Rehabilitation of older patients: day hospital compared with rehabilitation at home. A randomised controlled trial.

Parker SG, Oliver P, Pennington M, Bond J, Jagger C, Enderby PM, Curless R, Chater T, Vanoli A, Fryer K, Cooper C, Julious S, Donaldson C, Dyer C, Wynn T, John A, Ross D.

Health Technol Assess. 2009 Aug;13(39):1-143, iii-iv. doi: 10.3310/hta13390.

18.

TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial.

Olanow CW, Schapira AH, LeWitt PA, Kieburtz K, Sauer D, Olivieri G, Pohlmann H, Hubble J.

Lancet Neurol. 2006 Dec;5(12):1013-20.

PMID:
17110281
19.

Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study.

Witt K, Daniels C, Reiff J, Krack P, Volkmann J, Pinsker MO, Krause M, Tronnier V, Kloss M, Schnitzler A, Wojtecki L, Bötzel K, Danek A, Hilker R, Sturm V, Kupsch A, Karner E, Deuschl G.

Lancet Neurol. 2008 Jul;7(7):605-14. doi: 10.1016/S1474-4422(08)70114-5. Epub 2008 Jun 4.

PMID:
18538636
20.

Cognitive rehabiliation for Parkinson's disease demantia: a study protocol for a pilot randomised controlled trial.

Hindle JV, Watermeyer TJ, Roberts J, Martyr A, Lloyd-Williams H, Brand A, Gutting P, Hoare Z, Edwards RT, Clare L.

Trials. 2016 Mar 22;17:152. doi: 10.1186/s13063-016-1253-0. Erratum in: Trials. 2017 Mar 23;18(1):138.

Supplemental Content

Support Center